Bill

HR 3520

STAND Against Emerging Opioids Act

119th Congress Introduced by David Kustoff and 2 co-sponsors

The STAND Against Emerging Opioids Act classifies tianeptine and its analogues as controlled substances, aiming to prevent misuse and enhance public health safety.

Introduced in House

WeVote Research Nonpartisan

Bill Summary · HR 3520

Summary of HR 3520: STAND Against Emerging Opioids Act

Overview

The STAND Against Emerging Opioids Act (HR 3520) is a legislative proposal aimed at addressing the growing concern over emerging opioid substances, specifically targeting tianeptine and its analogues. The bill seeks to enhance regulatory measures to combat the opioid crisis by scheduling these substances under controlled substances laws.

Purpose and Intent

The primary intent of the STAND Against Emerging Opioids Act is to:
- Prevent misuse of tianeptine and its analogues, which have been associated with opioid-like effects and potential addiction.
- Strengthen public health responses to the opioid epidemic by ensuring that emerging substances are effectively regulated.

Key Provisions

Scheduling of Tianeptine: The bill proposes to classify tianeptine and its analogues as controlled substances, thereby imposing restrictions on their manufacture, distribution, and possession.
Regulatory Framework: It mandates the establishment of guidelines for the regulation of these substances, ensuring that they are monitored and controlled to prevent abuse.

Affected Parties

The legislation would impact:
- Manufacturers and Distributors: Companies involved in the production and distribution of tianeptine and its analogues would need to comply with new regulations.
- Healthcare Providers: Medical professionals prescribing or dispensing these substances would face new guidelines and restrictions.
- Consumers: Individuals using tianeptine for legitimate medical purposes may experience changes in availability and access.

Legislative Process

Introduced: The bill was introduced in the House on May 20, 2025.
Committee Referral: It has been referred to the Committee on Energy and Commerce and the Committee on the Judiciary for further consideration. The timeline for these committees to review the bill will be determined by the Speaker of the House.

Conclusion

The STAND Against Emerging Opioids Act represents a proactive approach to managing the risks associated with new opioid-like substances. By scheduling tianeptine and its analogues, the bill aims to mitigate potential health risks and enhance public safety in the face of an ongoing opioid crisis. As the bill progresses through the legislative process, further details and provisions may be developed to address the complexities of this issue.

Compiled from official sources — confirm details with the bill’s official record.